Determination of bupropion hydrochloride in rat plasma by LC-MS/MS and Its application to pharmacokinetic study

A selective and sensitive liquid chromatography-tandem mass spectrometry method was developed and validated for quantitation of bupropion hydrochloride in rat plasma using triazolam as an internal standard. Chromatographic separation was achieved on a SB-C18 column at 30 °C, with 50: 50 (v/v) acetonitrile-0.1 % formic acid in water as mobile phase. The flow rate was 0.3 mL/min. The determination of bupropion was performed in MRM mode, m/z 239.9 → 183.7 for bupropion and m/z 343.0 → 308.0 for triazolam (IS) and positive ion electrospray ionization interface. Calibration curve was linear over range of 1.2 to 480 ng/mL. The intra- and inter-run relative standard deviations of the assay were less than 10 %. The mean absolute recoveries determined at the concentrations of 2.4, 48 and 360 ng/mLwere 91.00%, 92.06%, 91.71%, respectively. The validated method is successfully used to analyze the drug in samples of rat plasma for pharmacokinetic study.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Determination of bupropion hydrochloride in rat plasma by LC-MS/MS and Its application to pharmacokinetic study

A selective and sensitive liquid chromatography-tandem mass spectrometry method was developed and validated for quantitation of bupropion hydrochloride in rat plasma using triazolam as an internal standard. Chromatographic separation was achieved on a SB-C18 column at 30 °C, with 50: 50 (v/v) acetonitrile-0.1 % formic acid in water as mobile phase. The flow rate was 0.3 mL/min. The determination of bupropion was performed in MRM mode, m/z 239.9 → 183.7 for bupropion and m/z 343.0 → 308.0 for triazolam (IS) and positive ion electrospray ionization interface. Calibration curve was linear over range of 1.2 to 480 ng/mL. The intra- and inter-run relative standard deviations of the assay were less than 10 %. The mean absolute recoveries determined at the concentrations of 2.4, 48 and 360 ng/mLwere 91.00%, 92.06%, 91.71%, respectively. The validated method is successfully used to analyze the drug in samples of rat plasma for pharmacokinetic study.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Correction: Associations of ACE Gene Insertion/Deletion Polymorphism, ACE Activity, and ACE mRNA Expression with Hypertension in a Chinese Population.

[This corrects the article DOI: 10.1371/journal.pone.0075870.]

Mesangial cell: A hub in lupus nephritis

Lupus nephritis (LN) is a severe renal disease caused by the massive deposition of the immune complexes (ICs) in renal tissue, acting as one of the significant organ manifestations of systemic lupus erythematosus (SLE) and a substantial cause of death in clinical patients. As mesangium is one of the primary sites for IC deposition, mesangial cells (MCs) constantly undergo severe damage, resulting in excessive proliferation and increased extracellular matrix (ECM) production. In addition to playing a role in organizational structure, MCs are closely related to in situ immunomodulation by phagocytosis, antigen-presenting function, and inflammatory effects, aberrantly participating in the tissue-resident immune responses and leading to immune-mediated renal lesions. Notably, such renal-resident immune responses drive a second wave of MC damage, accelerating the development of LN. This review summarized the damage mechanisms and the in situ immune regulation of MCs in LN, facilitating the current drug research for exploring clinical treatment strategies

Determination of bupropion hydrochloride in rat plasma by LC-MS/MS and Its application to pharmacokinetic study

A selective and sensitive liquid chromatography-tandem mass spectrometry method was developed and validated for quantitation of bupropion hydrochloride in rat plasma using triazolam as an internal standard. Chromatographic separation was achieved on a SB-C18 column at 30 °C, with 50: 50 (v/v) acetonitrile-0.1 % formic acid in water as mobile phase. The flow rate was 0.3 mL/min. The determination of bupropion was performed in MRM mode, m/z 239.9 → 183.7 for bupropion and m/z 343.0 → 308.0 for triazolam (IS) and positive ion electrospray ionization interface. Calibration curve was linear over range of 1.2 to 480 ng/mL. The intra- and inter-run relative standard deviations of the assay were less than 10 %. The mean absolute recoveries determined at the concentrations of 2.4, 48 and 360 ng/mLwere 91.00%, 92.06%, 91.71%, respectively. The validated method is successfully used to analyze the drug in samples of rat plasma for pharmacokinetic study.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial

Background The purpose of this study was to assess the efficacy, safety, and pharmacokinetics of cisplatin-based chemotherapy plus cetuximab as first-line treatment in Chinese and Korean patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Methods Patients (n = 68) received cetuximab weekly plus 3-week cycles of cisplatin/5-fluorouracil (5-FU) chemotherapy for up to 6 cycles. The primary endpoint was overall response rate. Results The overall response rate was 55.9%, including 2 complete responses (CRs). Median overall survival (OS) was 12.6 months and median progression-free survival (PFS) was 6.6 months. Grade 3/4 adverse events (AEs) were reported in 41 (60.3%) patients. The safety profile was in line with previous clinical experience. The pharmacokinetic profile was in line with that observed with cetuximab in white and Japanese patients. Conclusion The efficacy, safety, and pharmacokinetic findings from this study support the use of first-line platinum-based chemotherapy plus cetuximab in Chinese and Korean patients with recurrent and/or metastatic SCCHN (ClinicalTrials.gov NCT01177956). © 2014 The Authors Head & Neck Published by Wiley Periodicals, Inc. Head Neck 37: 1081–1087, 201